A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread (MONARCH 1)
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Sponsor: Eli Lilly and Company
This PHASE2 trial investigates Metastatic Breast Cancer and is currently completed. Eli Lilly and Company leads this study, which shows 15 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Oct 2019 — Feb 2020 [monthly]
Completed PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Completed PHASE2
-
Apr 2019 — Sep 2019 [monthly]
Completed PHASE2
-
Jan 2019 — Apr 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .